Alternatively, unless there are take overs or major partnership deals, Start-ups at IMU's stage of development tend to have a fairly "fixed" SP range. Maybe Platinum thought the funds could be used elsewhere until there was firm pressure on the SP that would benefit their clients.
Normally, phase 2 trials make or break a company - especially one that is essentially chasing a single medical technology (ie notwithstanding one with momentous capacity to be used universally for many medical conditions). It may just be strategic move until circumstance present a nearer ability to increase an investment.
I don't think we will see a dramatic shift in IMU's SO in 2018 BUT good results from phase2 trials next year will see it potentially increase several times over.
Add to My Watchlist
What is My Watchlist?
